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Background: Dyschromatosis symmetrica hereditaria (DSH) is an autosomal dominantly inherited skin disease
associated with mutations of ADAR1, the gene that encodes a double-stranded RNA-specific adenosine deaminase.
The purpose of this study was to investigate the potential mutations in ADAR1 in seven Chinese families with DSH.
Methods: All the coding exons including adjacent intronic as well as 5′ and 3′ untranslated region (UTR) of ADAR1
were screened by direct sequencing. Moreover, quantitative reverse-transcription polymerase chain (qRT-PCR) and
Western blot were applied to determine the pathogenic effects associated with the mutations.
Results: Molecular genetic investigations detected five novel mutations (c.556C > T, c.3001C > T, c.1936_1937insTG,
c.1065_1068delGACA and c.1601G > A resulting in p.Gln186X, p.Arg1001Cys, p.Phe646LeufsX16, p.Asp357ArgfsX47
and p.Gly471AspfsX30 protein changes, respectively) as well as two previously reported (c.2744C > T and c.3463C > T
causing p.Ser915Phe and p.Arg1155Trp protein changes, respectively). Among them, we found that the substitution
c.1601G > A at the last nucleotide of exon 2 compromised the recognition of the splice donor site of intron 2, inducing
an aberrant transcript with 190-bp deletion in exon 2 and causing an approximately 50% reduction of ADAR1 mRNA
level in affected individual. In addition, consistent with the predicted results, the expression patterns of other novel
mutations were detected by Western blot.
Conclusion: We identified five novel and two recurrent mutations of the ADAR1 gene in seven Chinese families with
DSH and investigated potential effects of the novel mutations in this study. Our study expands the database on
mutations of ADAR1 and for the first time, demonstrates the importance of exonic nucleotides at exon-intron
junctions for ADAR1 splicing.
Keywords: Dyschromatosis symmetrica hereditaria, ADAR1, in vivo mRNA assay, Exonic splicing mutation,
in vitro expression assayBackground
Dyschromatosis symmetrica hereditaria (DSH, MIM
#127400), also called symmetric dyschromatosis of the
extremities, is characterized by hyperpigmented and
hypopigmented macules on the face and dorsal aspects
of the extremities. The skin lesions usually appear from
infancy or early childhood, commonly stop spreading* Correspondence: luoyang@mail.cmu.edu.cn
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unless otherwise stated.before adolescence and last for life [1]. Generally showing
an autosomal dominant pattern of inheritance with high
penetrance, DSH has been reported in various parts of
the world, but predominantly in Japan and China [2,3].
RNA-specific adenosine deaminase 1 (ADAR1) gene,
located on chromosome 1q21.3, was identified to be
responsible for DSH [2].
ADAR1, also called DSRAD (double-stranded RNA-
specific adenosine deaminase), spans 30 kb and contains
15 exons [4]. It encodes RNA-specific adenosine deaminase
1 composed of 1226 amino acid residues, with a calculated
molecular mass of 139 kDa. Mammalian ADAR1 showsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Liu et al. BMC Medical Genetics 2014, 15:69 Page 2 of 10
http://www.biomedcentral.com/1471-2350/15/69ubiquitous expression and is supposed to be one of the
housekeeping genes. The enzyme catalyses the deamination
of adenosine (A) to isosine (I) in double-stranded RNA
substrates, which results in the creation of alternative spli-
cing sites or alternations of codon and thus lead to func-
tional changes in proteins [4].
In this study, we investigated seven families with DSH
in Chinese Han population and found five novel and two
recurrent mutations. We applied in vivo mRNA assays
and in vitro expression assays to investigate the effects of
these novel mutations and discussed their potential patho-
genic mechanisms.
Methods
Sample collection and ethics statement
Seven unrelated multi-generation DSH families exhibited
an autosomal dominant inherence patterns (Figure 1).
All affected individuals had typical macules on the dorsal
aspects of the hands and feet. These lesions, with irregular
shapes and sizes, appeared from early childhood, generally
ranging from 3 to 10 years (Figure 2A, 2B). The skin le-
sions became more pronounced after sun exposure. No
patient had extracutaneous symptoms. In family 3, the
affected individuals had hypopigmented and hyperpig-
mented macules around ankle and in family 4 and 5, small
freckle-like pigmented macules disturbed on the faces of
affected individuals. DSH was diagnosed by experienced
dermatologists based on the typical manifestations. The
study was approved by the Research Ethics Committee
of China Medical University and all the participants gave
written informed consent.
Extraction of genomic DNA and PCR
Genomic DNA samples were extracted from peripheral
blood using the Universal Genomic DNA Extraction Kit
(TaKaRa, Dalian, China). The primers that flanked all 15
coding exons and intron-exon boundaries of the ADAR1
were designed (Table 1). Using Taq DNA polymerase, all
fragments were amplified as follows: 1 min at 94°C,
30 cycles (30 sec at 94°C, 30 sec at 58°C, 1 min at 72°C)
and 5 min at 72°C. After the amplification, the products
were purified on agarose gels and subjected to sequencing.
RNA splicing analysis
Fresh peripheral blood samples were collected from the
affected individual and 3 healthy controls. Total RNA
was extracted using the TRIzol reagent according to the
manufacturer’s protocols. After quantification, 1 μg of
RNA sample was reversely transcribed into cDNA using
an AMV reverse transcriptase kit from TaKaRa Company
according to the manufacturer’s instructions. To analyze
the expression of the mutant ADAR1 allele, RT-PCR was
performed with primers E2F/E3R (Table 2) [5]. The cDNA
fragments were then subcloned into pMD 18-T vector andsubjected with sequencing. Moreover, RT-PCR was carried
out with primer pairs E1F/E3R and E1F/E4R to determine
whether there was exon skipping in affected individual.
Real-time quantitative RT-PCR
To quantify the relative mRNA expression of ADAR1 in
affected individual, real-time quantitative RT-PCR was
carried out using primer pairs E9-10 F/E10-11R (Table 2).
The amplicon of ADAR1 was 140 bp in length, normalized
by a 120-bp glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) fragment. Reactions were performed with SYBR
Green PCR Master Mix (TaKaRa) [5]. Three replicates of
each reaction were carried out and the 2-ΔΔCT method was
used to calculate relative changes in ADAR1 expression.
Melting curve analysis confirmed that only the expected
product was amplified [5].
In vitro expression assay
The wild-type coding sequence of ADAR1 was amplified
from pCMV6-ADAR1 (Origene) by PCR and subcloned
into pFLAG-CMV-2 (Sigma-Aldrich, St. Louis, MO, USA)
at its Not I restriction site by standard procedure. To
generate mutant plasmids, site-directed mutagenesis
using PCR-based method was applied. Concisely, primers
were designed for mutagenesis and fragments amplified
by PCR were subcloned into pFLAG-CMV-2 vector using
a standard subcloning protocol, respectively. After con-
firmed by sequencing, all plasmids were transfected
into human embryonic kidney (HEK-293) cells, respect-
ively [6]. The whole cellular lysates were extracted at 48 h




Among 7 Chinese families with DSH, we found 5 novel
mutations in ADAR1 (Table 3). The spectrum of mutations
included one nonsense mutation, two missense mutations,
one small insertion and one small deletion, all of which
were heterozygous (Figure 2C-G). Searching the Human
Gene Mutation Database (HGMD) and PubMed, we
did not find the reports about these variants. All the
mutations segregated affected individuals from 100
normal Chinese subjects, suggesting that neither of them
was a polymorphism (For point mutations c.556C > T,
c.3001C > T and c. 1601G > A, PCR-RFLP was applied
with restriction endonuclease Bsp1407I, Bgl II and Sca I
while for small insertion/deletion c.1936_1937insTG and
c.1065_1068delGACA, SDS-PAGE was applied after PCR
amplification, respectively).
In the family 1, the nonsense mutation was detected in
exon 2 of ADAR1 and defined as c.556C > T (Figure 2C).
This mutation was suggested leading to a truncated
ADAR1 protein lacking 1040 amino acid residues. In
Figure 1 Family Pedigrees in this study. Seven multi-generation families with DSH illustrated autosomal dominant inherence pattern with 29
affected individuals. (A-G) Pedigrees of the studied DSH family 1-7. Affected family members are presented by black symbols. The probands
are arrowed.
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Figure 2 (See legend on next page.)
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Figure 2 Typical skin lesions and mutations of the ADAR1 gene. (A, B) A mixture of hyperpigmented and hypopigmented macules distributed
on the dorsal aspects of hands and feet of the proband of family 4 (III1); (C-G, I-J) Direct DNA sequencing showing the five novel mutations in the
family 1–5 (C-G) and the two recurrent mutations in family 6 and 7 (I, J), respectively; (H) ClustaIW multiple alignment of various species around
residue 1001 of human ADAR1.
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was identified by sequencing (Figure 2D). This mutation
replaced arginine residue with cysteine, which was shown
as a highly conserved residue within the functional domain
of the ADAR1 (Figure 2H).
Moreover, nucleotides TG were found to insert between
c.1936 and c.1937 in the family 3 and this 2-bp small
insertion induced a frameshift from codon 646 and ex-
pected to produce a premature termination codon (PTC)
at codon 661 (Figure 2E). In addition, one 4-bp small dele-
tion, c.1065_1068delGACA, was detected in the family 4.
This mutation might shift the reading frame and generate
a PTC at codon 403 (Figure 2F).
Furthermore, direct sequencing of ADAR1 revealed a
missense substitution, c. 1601G >A, at the end of exon 2 in
the family 5 (Figure 2G). Since this G nucleotide belongs
to the conserved exon-intron junction, we performedTable 1 Primers and conditions used in PCR for ADAR1 gene






















Reverse: GCTACGACCTACCTCTCTCACACCCsplicing predictions with web-based resources. Analysis
with SpliceView (http://zeus2.itb.cnr.it/~webgene/wwwspli-
ceview_ex.html) and Human Splicing Finder (http://www.
umd.be/HSF/) indicated that the recognition of such splice
donor site was potentially attenuated in the presence of
c.1601G >A, supporting that this mutation might play a
role in splicing process.
Moreover, two recurrent mutations, c.2744C > T and
c.3463C > T, were detected in family 6 and 7, respectively
(Figure 2I, 2J). Both of them were missense mutations,
suggesting the replacements of serine 915 by phenylalan-
ine and arginine 1155 by tryptophan, respectively [8,9].
Molecular analysis of expression patterns of the novel
mutations
Furthermore, we attempted to determine the exact conse-















Table 2 Primer sequences used in RT-PCR and real-time
quantitative RT-PCR
RT-PCR E1F: 5′-GAGGAAACGAAAGCGAAATTGAACCGGA-3′
E2F: 5′- AACTCCACATCTGCCTTGGAAGATCCTC -3′
E3R: 5′-CTCTCGGCCATTGATGACAACCTGGAAT-3′
E4R: 5′-TGTGCATACACTCAAGCAGTGTGGTGAC-3′
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splicing patterns between affected individual and healthy
control. While predicted 780-bp PCR fragments of normal
splicing were shown and confirmed by sequencing analysis
both in the affected and healthy individual, an additional
about 600-bp PCR product was shown in the presence
of mutant and subsequently subcloned into pMD18-T
(Figure 3A, 3B). Direct sequencing of TA clones revealed
that this mutation caused a splicing error in ADAR1. With
functional loss of the native intron 2 donor site, this
mutation activated the cryptic splicing donor site GT
lying upstream of the normal splicing donor site in exon
2 and thus caused a 190-bp deletion in mRNA sequence
(Figure 3C). Hence, this c.1601G >A mutation was ex-
pected to shift the reading frame from codon 471 with 29
aberrant amino acids and generate premature termination
at codon 500. Moreover, no additional band was detected
in RT-PCR assays using the primer pairs E1F/E3R and
E1F/E4R, excluding the possibility of exon skipping in
affected individual due to this mutation (data not shown).
Upon the worthwhile observation that the aberrant
transcript was present at much reduced level in the af-
fected individual, mRNA quantification was evaluated
with real-time quantitative RT-PCR. By validating with
the 2-ΔΔCT method, the relative quantities were 0.525,
0.639 and 0.467 (mean ± SD, 0.54 ± 0.09) for individual
carrying with c.1601G >A mutation compared with healthyTable 3 Mutations of the ADAR1 gene identified in this study
Patient Part of lesions Mutation
Nucleotide change
1 Back of hands and feet c.556C > T
2 Back of hands and feet c.3001C > T
3 Back of hands and feet, ankles c.1936_1937insTG
4 Back of hands and feet, face c.1065_1068delGAC
5 Back of hands and feet, face c.1601G > A
6 Back of hands and feet c.2744C > T
7 Back of hands and feet c.3463C > Tsubject, indicating an approximately 50% reduction of the
ADAR1mRNA expression in affected individual.
Since fresh blood samples from affected individuals of
family 1 to 4 were not available, we continued to investigate
the expression patterns of these mutants with in vitro ex-
pression assays. Briefly, immunoblottings were performed
with lysates of HEK-293 cells overexpressing wild-type or
mutants of ADAR1. Consistent with the predicted results,
the truncated ADAR1 proteins were detected as 21 kDa in
cells overexpressing c.556C > T mutation, 75 kDa in cells
overexpressing c.1936_1937insTG mutation and 46 kDa
in cells overexpressing c.1065_1068delGACA mutation,
respectively (Figure 4). Moreover, as a missense mutation,
c.3001C > T (p.Arg1001Cys) mutant demonstrated the
same molecular weight as the wild-type ADAR1 protein.
Discussion
A-to-I RNA editing is one of the post-transcriptional
modifications widespread in mammals, which modifies
adenosine (A) base in pre-mRNA to yield inosine (I) [10].
Since I is recognized as guanosine during translation,
A-to-I RNA editing in coding sequences probably leads
to amino acid changes which often entails changes in
protein function [10]. Moreover, editing A-to-I modifica-
tion might alter splice patterns as well as RNA structures
and stabilities [1,10,11]. A-to-I editing is catalyzed by
ADARs in vertebrate and till now, three ADAR family
members, ADAR 1–3, have been identified. Among them,
ADAR1 was confirmed to be responsible for DSH in 2003
[1]. To date, the mechanisms by which ADAR1 mutations
cause DSH still remain unclear [10,11].
Human ADAR1 contains, from N- to C-terminals,
two adenosine deaminase Z-alpha (Zα) domains, three
double-stranded RNA binding motifs (DSRMs) and a
tRNA-specific and double-stranded RNA adenosine de-
aminase (ADEAMc) domain, which encodes by exon 2,
2–7 and 9–15 of ADAR1, respectively [5]. Although
ADEAMc is the catalyze domain for A-to-I modification,
Zα and DSRM domains are also essential for the activity
of ADAR1 [5,11-14].Mutation effect








Figure 3 Aberrant splicing pattern of ADAR1 caused by c.1601G > A mutation. (A) Locations of primers used in RT-PCR; (B) RT-PCR analysis
revealed a transcript abnormality in ADAR1; (C) cDNA sequencing and predicted amino acid sequence of the aberrant (left) and normal (right)
transcripts of ADAR1; (D) The relative quantities of ADAR1 mRNA level derived from real-time quantitative RT-PCR.
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Figure 4 In vitro expression assays. Total cellular lysates of HEK-293 cells transfected with FLAG-tagged wild-type or mutant plasmids were
immunoblotted with FLAG antibody. beta-tubulin was used as an internal control.
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recurrent mutations. Among them, the nonsense mutation
c.556C >T (p.Gln186X) and small deletion c.1065_1068del-
GACA (p.Asp357ArgfsX47) are expected to cause ADAR1
truncations lacking the entire three DSRMs and ADEAMc
domain while c.1936_1937insTG (p.Phe646LeufsX16),
the small insertion identified in our study, supposes to
change the reading frame from the second DSRM and
induces truncated ADAR1 protein without the last
DSRM and ADEAMc domain (Figure 5). In addition,
Figure 4 suggested that the mutations c.556C > T and
c.1065_1068delGACA might reduce the expression of
mutant proteins and we speculated that the nonsense-
mediated mRNA decay (NMD) might be one of the
possibilities. For the missense mutations c.3001C > T
(p.Arg1001Cys), c.2744C >T (p.Ser915Phe) and c.3463C >
T (p.Arg1155Trp), the transitions of nucleotides changeFigure 5 Novel mutations of ADAR1 identified in this study. The funct
Z-DNA binding domains; DSRM: double stranded RNA binding domains; ADcodons in the highly conserved region of ADEAMc do-
main, which possibly alter the activity of ADAR1 directly,
or by disturbing the formation of wild-type ADAR1 homo-
dimers [9]. In family 5, the aberrant splicing decreased ap-
proximately half ADAR1 mRNA level, potentially caused
by NMD, supporting that haploinsufficiency of ADAR1
produces DSH [5,9]. In addition, we compared the clinical
features with the mutations indentified in all the families
but failed to find any clear relationship between pheno-
types and genotypes as other groups have reported [2,13].
Till now, about 145 ADAR1 mutations have been re-
ported in DSH patients, which consist of 80 missense
and nonsense mutations, 11 splicing mutations, 37 small
deletions, 14 small insertions, 2 small indels and 1 gross
insertion [15-29]. So far, most known missense mutations
(49 in 57, 86%) are located within the ADEAMc domain
encompassing amino acids 839–1222 [3]. The missenseional domains (Zα, DSRM, ADEAMc) were indicated in the figure. Zα:
EAMc: deaminase domain.
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domain. These data support that the ADEAMc domain is
critical for this enzyme and indicates that this region
might be hot spot for mutation within ADAR1 [10,16,17].
To date, 23 nonsense mutations have been reported in
ADAR1 and they appear to distribute throughout the gene
without apparent unifying connection. Till now, 11 splicing
mutations have been identified, all of which situate in
ADAR1 introns. Among them, only 4 mutations were
further studied with cDNA sequence analysis and detected
the aberrant splicing products [20,21,27], in which 3 spli-
cing mutations led to skipping one or more exons near to
the mutations [27], and the other one was a in-frame mu-
tation which generated a 4-amino acid deletion in ADAR1
protein [21]. To our knowledge, the c.1601G >A mutation
identified in our study is the first report about the exonic
splicing mutation in ADAR1.
Although ADAR1 expressed ubiquitously in mammalian
tissues and playing various roles such as viral host defense,
embryonic development, tumor growth and miRNA pro-
cessing [22-25], only a few its target genes including the
neurotransmitter receptors in the central nervous system
and the hepatitis virus antigen in the liver are identified
[9]. Therefore, mutations in the ADAR1 might associate
with neurological dysfunction such as dystonia and mental
deterioration [26]. However, like most affected individuals
reported previously, patients in our study only show pig-
mentary abnormality in skin without obvious dysfunction
in extracutaneous tissues. Recently, mutations identified
in ADAR1 were reported to be relevant with autoimmune
disorder, hair color change and dental abnormality [15,27].
Thus, further investigation on the mechanisms by which
ADAR1 regulates its target genes in different tissues will
facilitate the understanding of ADAR1 functions.
Driven by different promoter, ADAR1 has been charac-
terized into two isoforms, an interferon-inducible 150 kDa
protein (p150) and a constitutively-expressed 110 kDa
protein (p110), in mammalian cells [1,2]. The p150 isoform,
translated from the methionine initiation codon, is the full
length protein mainly distributed in cytosol while the p110
isoform initially translates from the AUG at codon 296 and
locates in the nucleus [28]. Till now, including p.Gln186X
identified in our study, four mutations of ADAR1 have been
reported at the 5′ side of codon 296 [2,29]. However, the
distinct roles of the isoforms are obscure. Recently, Zhang
et al. reported that the small deletion p.R91fsX123 could
eliminate the expression of the p150 transcript through
NMD, while did not significantly alter the expression of
p110 in patients of DSH, indicating that p150 isoform of
ADAR1 might be the determinant of DSH [29].
Conclusion
In conclusion, we identified five novel and two recurrent
mutations of the ADAR1 gene in seven Chinese familieswith DSH and investigated potential effects of the novel
mutations in this study. Together with previous related
studies, these results might give insight into the still
unknown mechanisms leading to DSH. Additionally,
our results enrich the ADAR1 mutation database and
will contribute further to the understanding of DSH
genotype/phenotype correlations as well as to the patho-
genesis of this disease.
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